Immunovant Inc

IMVT has decisively broken below a key horizontal support zone with a sharp red candle, confirming an active Support Failure pattern. Medium-term bias is bearish as broken support now acts as resistance under Stage 3 distribution conditions. Short-term execution is deferred—the price is extended below declining EMAs and RSI is in extreme oversold territory, suggesting waiting for a rally into EMAs before selling. The long-term uptrend remains intact above the rising 200-day SMA.

• ↑$797.8M cash as of June 30, 2026 provides runway for pivotal trials.
• ↑Upcoming IMVT-1402 Graves’ trial data readouts expected in 2026.
• ↓Q1 net loss of $0.75/share vs. $0.66 consensus highlights widening losses.